Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig's disease, is a rare but terminal neurodegenerative disorder that leads to the progressive loss of upper and lower motor neurons, resulting in muscle stiffness, weakness, and ultimately complete paralysis, including the loss of the ability to eat, speak, move, and breathe. ALS has no cure and can also cause cognitive difficulties in about 50% of those affected.
Health Outcomes
- Activated Mitophagy Pathway
- Decreased Vastus Medialis Thickness
- Delayed Neurodegeneration
- Enhanced Autophagy
- Enhanced Neurological Disorder Management
- Enhanced Reactive Oxygen Species Resistance
- Enhanced Superoxide Dismutase Activity
- Facilitated Mitophagy
- Impaired Vacuolar Function
- Improved ALSFRS-R Score
- Improved Amyotrophic Lateral Sclerosis Outcome
- Improved Communication Skills
- Improved Gait Speed
- Improved Gross Motor Function
- Improved Leg Strength
- Improved Maximal Voluntary Contraction
- Improved Motor Function
- Improved Motor Symptom
- Improved Muscle Composition
- Improved Muscle Function Recovery
- Improved Muscle Integrity
- Improved Neurodegenerative Disease Symptoms
- Improved Neurodegenerative Disorder
- Improved Neurological Health
- Improved Neurological Symptoms
- Improved Neuromuscular Power
- Improved Neuromuscular Strength
- Improved Neuronal Survival
- Improved Neuroprotection
- Improved Power-Related Outcome
- Improved Reaching Ability
- Improved Serum Biochemical Catalase Levels
- Improved Skeletal Muscle Damage
- Improved Superoxide Dismutase Activity
- Improved Thigh Muscle pH Value
- Improved Upper Body Strength
- Improved Vertical Jump
- Improved Walking Ability
- Increased Apoptosis
- Increased Autophagy
- Increased Cysteine Level
- Increased Neuronal Cell Survival
- Increased Oxidative Stress Tolerance
- Increased Serine Level
- Increased Superoxide Dismutase Activity
- Maintained Cytoskeletal Integrity
- Maintained Muscle Integrity
- Nervous System Dysfunction in Host
- Neuroprotection in Neurodegenerative Diseases
- No Significant Improvement in Locomotor Activity
- Preserved Wheel-Running Activity
- Prevention of Neurological Disorders
- Reduced Brain Inflammation
- Reduced Choking Index
- Reduced Cytoskeleton Disruption
- Reduced Dysphagia
- Reduced Dysphagia Symptom Score
- Reduced Ferroptosis
- Reduced Glial Cell Activation
- Reduced Glutamate Level
- Reduced Lean Mass
- Reduced Locomotor Impairment
- Reduced Muscle Thickness
- Reduced Muscle Wasting
- Reduced N-acetylaspartate Level
- Reduced Neurodegeneration Symptoms
- Reduced Neurodegenerative Disease-Related Dysfunction
- Reduced Neuroinflammation
- Reduced Neuroinflammatory Markers
- Reduced Neurological Symptoms
- Reduced Neuronal Death
- Reduced Neurotoxicity
- Reduced Peak Inspiratory Pressure
- Reduced Proteotoxicity
- Reduced Quadriceps Muscle Cross-Sectional Area
- Reduced Serum Glutamate Levels
- Reduced Swimming Time
- Regulated Microglial Activation
- Restored Neurodegeneration-Associated Metabolic Alterations
- Stabilized Disease Progression
- Stabilized Neurofilament Light Chain Level